Gossamer Bio Inc
$ 0.42
-1.87%
24 Feb - close price
- Market Cap 96,147,000 USD
- Current Price $ 0.42
- High / Low $ 0.44 / 0.36
- Stock P/E N/A
- Book Value -0.36
- EPS -0.69
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -7.83 %
- 52 Week High 3.87
- 52 Week Low 0.33
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapies in the areas of immunology, inflammation, and oncology diseases in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$7.72
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-09 | 2023-08-08 | 2023-05-09 | 2023-03-17 |
| Reported EPS | -0.21 | -0.17 | -0.16 | -0.15 | -0.14 | 0.22 | -0.19 | -0.21 | -0.21 | -0.45 | -0.52 | -0.59 |
| Estimated EPS | -0.19 | -0.1805 | -0.19 | -0.168 | -0.15 | 0.23 | -0.19 | -0.21 | -0.26 | -0.49 | -0.53 | -0.62 |
| Surprise | -0.02 | 0.0105 | 0.03 | 0.018 | 0.01 | -0.01 | 0 | 0 | 0.05 | 0.04 | 0.01 | 0.03 |
| Surprise Percentage | -10.5263% | 5.8172% | 15.7895% | 10.7143% | 6.6667% | -4.3478% | 0% | 0% | 19.2308% | 8.1633% | 1.8868% | 4.8387% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GOSS
2026-02-24 14:53:12
Gossamer Bio (NASDAQ: GOSS) shares plummeted after the company reported Phase 3 PROSERA study results for seralutinib in pulmonary arterial hypertension, which narrowly missed a key statistical threshold, despite being an active treatment option. Following this news, analysts from Leerink Partners, Barclays, and Wedbush downgraded the stock and significantly cut their price targets. Gossamer Bio plans to discuss the findings with the FDA and present data showing greater activity in patients with advanced disease.
2026-02-24 12:53:12
Leerink has downgraded Gossamer Bio (GOSS) from Outperform to Market Perform and significantly lowered its price target from $6 to $1. This adjustment reflects a revised outlook on the biotechnology company. Gossamer Bio is currently focused on developing seralutinib for pulmonary arterial hypertension (PAH) and is in a Phase III clinical trial for this treatment.
2026-02-23 17:53:12
Gossamer Bio Inc. (GOSS) has released topline data from its Phase III Prosera study, evaluating Seralutinib for pulmonary arterial hypertension. This is a significant step for the company, as Seralutinib, if approved, could offer a new treatment option for this rare and severe disease with unmet clinical needs. The results will inform future research and development decisions and the drug's marketing application strategy.
2026-02-23 17:28:09
Block & Leviton is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) for potential securities law violations after the company's shares fell over 75% due to the failure of its Phase 3 PROSERA trial. Investors who suffered losses are encouraged to contact the law firm to explore options for recovering their investments. The investigation aims to determine if the company committed securities law violations.
2026-02-23 17:16:30
Block & Leviton is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) for potential securities law violations after the company's shares fell over 75%. This significant drop occurred on February 23, 2026, following the announcement that its Phase 3 PROSERA trial failed to meet its primary endpoint. The law firm is encouraging investors who have lost money to contact them to explore options for recovering losses.
2026-02-23 16:42:49
Johnson Fistel, PLLP is investigating potential claims against Gossamer Bio, Inc. (NASDAQ: GOSS) on behalf of investors who suffered losses. This investigation follows the announcement of topline results from Gossamer's Phase 3 PROSERA trial, where the primary endpoint for seralutinib did not meet statistical significance, leading to a significant stock decline. The law firm is examining whether Gossamer Bio complied with federal securities laws.
